Any study of recurrence at 5=10 years is missing the point about rising risk for, say, years 10-15.

All we have is genomic tests at the moment. If they say risk is, like mine, 12% without meds and 6% with meds, and my pathology was relatively scary, I don't think that is far off from the average of 1 in 49. It is more about your chances of being that one!

I think forums tend to the negative and more people who have bad side effects tend to post. So I am glad there is balance in this forum with some, including me, posting more positive experiences.

Protocols change and we need to keep up. Breast Cancer Index is now in the NCCN guidelines. I had the Breast Cancer Index at year 5 of Femara and it told me there was no benefit in continuing meds in years 5-10. Desepite very high ER and PR scores of 95%. Oncotype is used for years 1-5. Many women are continuing meds after 5 years with no benefit. From the site:

"Nearly 95% Of Women With Early-Stage, Hormone Receptor–Positive (HR+) Breast Cancer Do Not Benefit From Extended Endocrine Therapy"

However, my risk was 5.7% for recurrence and was labelled at the time as "high." You can have high risk, no benefit, low risk, positive benefit, high risk, positive benefit and low risk, no benefit.
https://www.breastcancerindex.com/resources-providers?gclid=265aff4aaa6b1c1dac6d9d9e2aff082b&gclsrc=3p.ds&msclkid=265aff4aaa6b1c1dac6d9d9e2aff082b&utm_source=bing&utm_medium=cpc&utm_campaign=Biotheranostics_BCI_HCP&utm_term=Breast%20Cancer%20Index&utm_content=hcp_breast%20cancer